<DOC>
	<DOCNO>NCT00549198</DOCNO>
	<brief_summary>Recently , fixed-dose combination ( FDC ) KIVEXA™ ( abacavir/lamivudine ) TRUVADA ( tenofovir disoproxil fumarate/emtricitabine ) facilitate usage once-daily regimen . However data head-to-head randomize trial compare two FDCs part initial regimen available present . The long-term toxicity profile regimens particular importance , treatment HIV currently life-long therefore , minimize long-term toxicity maximize adherence duration regimen maintenance critical therapy objective . The primary endpoint estimate glomerular filtration rate ( GFR ) , measure modify diet renal disease ( MDRD ) equation , validated estimate renal function .</brief_summary>
	<brief_title>KIVEXA Vs TRUVADA , Both Administered With Efavirenz , In ART-Naive Subjects</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Subject least 18 year age . Subject antiretroviralnaïve ( define previous therapy NNRTI 14 day prior therapy antiretroviral ) . Subject plasma HIV1 RNA 1,000 copies/mL screening . This test may repeat within 45day screen window . Subject willing able understand provide write informed consent prior participation study . A female eligible enter participate study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ) ; , 2 . Childbearing potential , negative pregnancy test screen agree one follow method contraception ( contraception method must use consistently correctly , i.e. , accordance approve product label instruction physician ) : Complete abstinence intercourse 2 week prior administration investigational product , throughout study , least 2 week discontinuation study medication Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) . Hormonal contraception consider adequate inclusion study Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year . Sterilization ( female subject male partner female subject ) . Prior randomization , subject must screen negative HLAB*5701 allele . Test may perform local laboratory result must available source document verification accord local practice . Subject initial acute phase CDC Clinical Category C infection Baseline . Subject enrol one investigational drug protocol , may impact HIV RNA suppression . Subject , opinion Investigator , unable complete study dose period protocol evaluation assessment . Subject either pregnant breastfeeding . Subject suffers serious medical condition , opinion Investigator would compromise safety subject . Subject history inflammatory bowel disease gastrointestinal dysfunction . Subject acute laboratory abnormality screening . Subject estimate creatinine clearance within screen period &lt; 50mL/min via CockcroftGault method . Alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal . Subjects history thyroid disease , hyperparathyroid disease , chronic hyper hypocalcemia , vitamin D deficiency , receive thyroid hormone parathyroid hormone replacement within 28 day prior screen . Subjects history systemic inflammatory arthritis . Subjects hepatitis B positive screening . Subject require treatment radiation therapy cytotoxic chemotherapeutic agent . Subject receive treatment HIV1 immunotherapeutic vaccine agent documented activity HIV1 vitro within 28 day prior Screening , anticipate need study . Subjects require treatment follow medication within 28 day commencement investigational product , anticipate need study : Medications significant drugdrug interaction efavirenz : voriconazole , terfenadine , astemizole , cisapride , ergot alkaloid ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) , midazolam , triazolam , St. John 's wort , carbamazepine , phenytoin , phenobarbital , rifampin , pimozide , bepridil Medications may impact bone mineral density : oral systemic corticosteroid , anticonvulsant , heparin , warfarin , cyclosporine , bisphosphonates , calcitonin , parathyroid hormone , Vitamin D supplement analogue , Calcium supplement , oestrogen progesterone replacement ( oral hormonal contraception permit ) , raloxifene , tamoxifen , testosterone anabolic steroid replacement/supplements . Systemic interleukins interferon Subject history allergy protocolspecified medication excipients therein . Subject evidence genotypic resistance screening ( accord central lab interpretation ) prior document evidence genotypic and/or phenotypic ( threshold reduce susceptibility ) resistance follow drug : efavirenz , abacavir , lamivudine , tenofovir , emtricitabine . Subjects unsuitable DEXA scanning exclude , include 1 ) Less three vertebra range L1 L4 suitable BMD measurement DEXA , 2 ) Bilateral hip replacement . The subject previously participate experimental drug and/or vaccine trial ( ) within 60 day 5 halflives , twice duration biological effect experimental drug vaccine whichever longer , prior screen study . The subject participate simultaneously another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>tenofovir</keyword>
	<keyword>HIV</keyword>
	<keyword>efavirenz</keyword>
	<keyword>naive</keyword>
	<keyword>lamivudine</keyword>
	<keyword>abacavir</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>renal</keyword>
</DOC>